The FDA just approved the world's first mRNA flu vaccine, and it's not the revenue that matters. Moderna's mFLUSIVA could reshape how regulators, investors, and competitors think about mRNA technology forever.
For five years, mRNA had a reputation problem. Sure, it saved the world during COVID-19. But skeptics (and more than a few investors) treated it like a one-trick pony: great for a pandemic, unclear for everything else. Could the technology actually work for normal, everyday vaccines?
On August 5, the FDA answered that question with a resounding yes.
The Approval That Changes the Conversation
Moderna's mFLUSIVA just became the first mRNA flu vaccine ever approved. The FDA cleared it for adults 50 and older, making it the first mRNA vaccine approved for a disease other than COVID-19 or RSV. (Moderna's RSV shot, mRESVIA, quietly crossed that threshold back in 2024, but flu is a much bigger commercial stage.)
The regulatory details are worth noting. Adults aged 50 to 64 received traditional approval, the gold standard. Adults 65 and older got accelerated approval, which means Moderna still needs to deliver confirmatory data for that age group. Think of it like getting your diploma but still owing one final paper.
Still, the signal is unmistakable: regulators now treat mRNA as a legitimate platform for routine vaccines, not just an emergency pandemic tool.
How Good Is This Flu Shot, Really?
Let's talk numbers, because they require some context.
The pivotal Phase 3 trial enrolled over 40,800 adults aged 50 and older. Moderna didn't test mFLUSIVA against a placebo; it tested the vaccine head-to-head against a standard-dose flu shot already on the market. That's a tougher bar to clear, because you're not asking "does this work?" but rather "does this work better than what people already get?"
The answer: 26.6% better. That was the relative vaccine efficacy against lab-confirmed flu with flu-like symptoms. The 95% confidence interval ran from 16.7% to 35.4%, comfortably clearing the study's prespecified goals for both noninferiority and superiority.
For people 65 and older specifically, the number was nearly identical at . And when researchers looked at more serious outcomes (ER visits, hospitalizations, urgent care), the advantage jumped to in one analysis. That last number matters a lot, because hospitalizations are where flu really hurts, both for patients and for the healthcare system.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
27.4%
47.9%
On safety, the picture was straightforward. More arm soreness, more fatigue, more of the "I feel like I got vaccinated" experience compared to the standard shot. But serious adverse events were rare and similar between the two groups. No new safety signals. If you've had an mRNA COVID vaccine, you know the general vibe.
The Strain-by-Strain Breakdown
mFLUSIVA performed consistently across different flu strains, which is important because flu is a shapeshifter that reinvents itself every season. Against H1N1, relative efficacy was 29.6%. Against the notoriously tricky H3N2 (the strain that causes the worst flu seasons), it was 22.2%. Against B/Victoria, it came in at 29.1%.
None of these numbers will blow your hair back individually. But remember the comparator here: this isn't versus nothing, it's versus an already-approved flu vaccine. Beating an existing product by a quarter or more across all major strains is clinically meaningful, especially for a technology that can be updated faster than egg-based manufacturing allows.
Why This Matters Way Beyond the Flu
If you're thinking "cool, another flu shot, who cares," you're missing the forest for the trees.
The seasonal flu vaccine market is worth roughly $7 to $9 billion globally. It's dominated by a handful of companies (Sanofi, CSL Seqirus, and GSK lead the pack), and the technology hasn't fundamentally changed in decades. Egg-based vaccines still account for over 69% of the market. Inactivated vaccines represent more than 91% of all flu shots sold.
Moderna just kicked the door open to a market that was, frankly, overdue for disruption. mRNA vaccines don't need eggs. They can be manufactured faster. And they can be redesigned quickly when new strains emerge, which is the whole reason flu vaccines sometimes underperform in a given year.
But the real significance isn't commercial. It's regulatory precedent.
Every mRNA program in Moderna's pipeline (and BioNTech's, for that matter) just got a little less risky. The FDA has now approved mRNA vaccines for three different diseases: COVID-19, RSV, and influenza. That's not a fluke. That's a pattern. And patterns matter enormously when you're trying to get the next mRNA product through regulatory review.
Moderna's Pipeline Just Got a Credibility Boost
Moderna isn't stopping at flu. The company's pipeline tells the story of where mRNA wants to go next.
mRESVIA, the RSV vaccine, is already on the market for adults 60 and older. It was the first non-COVID mRNA approval in 2024, and it's now sold in multiple countries.
The flu/COVID combination vaccine (mRNA-1083) has completed Phase 3 with positive results, though its U.S. regulatory filing was voluntarily withdrawn in May 2025. Imagine getting your annual flu shot and COVID booster in a single jab. That's the pitch, and if it works commercially, it could reshape how we think about fall respiratory season.
The CMV program (mRNA-1647) hit a speed bump, though. Moderna discontinued its congenital CMV development and is only continuing a Phase 2 study in bone marrow transplant patients. CMV (cytomegalovirus, a common virus that can cause serious birth defects) was supposed to be one of Moderna's crown jewels. Losing that program stings.
The broader picture: Moderna now has two commercial mRNA products outside of COVID, a combination vaccine program advancing toward regulatory review, and a pandemic flu program in collaboration with CEPI still in Phase 3. The platform thesis is becoming harder to dismiss.
Wall Street Yawned (and That's Actually Fine)
You might expect a historic FDA approval to send Moderna's stock soaring. It didn't. Shares barely moved on the news, ticking down a fraction of a percent.
The reason is timing. Moderna missed the 2026 U.S. flu contracting cycle, which means pharmacies and health systems have already ordered their flu vaccines for this fall. Analysts don't expect meaningful mFLUSIVA revenue until the second half of 2027. It's like releasing a blockbuster movie the week after everyone already bought tickets to something else.
The analyst consensus is clear: bullish on the long-term strategic value, cautious on near-term revenue impact. mFLUSIVA is the first and only standalone mRNA flu vaccine on the market. That positioning matters. But it won't show up in earnings for a while.
For Moderna, which has been burning through cash as COVID vaccine demand fades, the question isn't whether mFLUSIVA is good science. It's whether the company can commercialize it fast enough to offset declining pandemic-era revenue. The 2027 flu season will be the real test.
The Flu Market Is Now a Three-Way Technology Fight
Zoom out, and the flu vaccine market is turning into something it hasn't been in decades: genuinely competitive on a technology level.
You've got egg-based vaccines, the incumbents, still commanding the majority of the market through sheer manufacturing scale and decades of infrastructure. You've got recombinant vaccines (like Sanofi's Flublok), which skip eggs entirely and are growing fast. And now you've got mRNA, which promises faster updates and potentially better immune responses.
Think of it like the streaming wars, but for immunology. The legacy players have distribution. The newcomers have better technology. And the winner probably isn't going to be determined by which approach is scientifically coolest; it'll be determined by who can manufacture at scale, negotiate with payers, and convince doctors and pharmacists to stock their product.
Moderna's challenge is real. Convincing a market that has relied on egg-based production for 70+ years to switch to mRNA won't happen overnight. But the company now has something it didn't have before: an FDA-approved product to sell the story with.
The Bottom Line
mFLUSIVA isn't going to transform Moderna's balance sheet tomorrow. But it might be the most important mRNA approval since the original COVID vaccines.
For five years, the knock on mRNA was simple: "prove it works for something else." Moderna just did, in the biggest routine vaccine market in the world. The technology has officially graduated from pandemic hero to pharmaceutical platform.
Now comes the hard part: winning a market that wasn't exactly begging for reinvention.
Deals & M&A
4 min read
BioCryst Just Killed Its Own Lab. Here's Why That Might Be Brilliant.
BioCryst is shutting down its 40-year-old internal drug discovery operation and betting everything on external deals. The rare-disease biotech is profitable, growing, and making a deliberate strategic gamble that could redefine what a mid-cap biotech looks like.
